ライフサイエンスコーパス: treatment plan

1 However, reactivation can affect the cancer treatment plan.

2 heir expressed concern and their recommended treatment plan.

3 therapy including an individualized surgical treatment plan.

4 and how CBCT influenced the diagnosis and/or treatment plan.

5 tates a specific and detailed assessment and treatment plan.

6 malignancy, with surgery being part of their treatment plan.

7 on the side of the prostate with a change in treatment plan.

8 ment plan, and milestones for evaluating the treatment plan.

9 dentifying underlying causes and tailoring a treatment plan.

10 ffer good care and patients to engage in the treatment plan.

11 ld be expected and factored into the overall treatment plan.

12 crucial step in diagnosis and monitoring the treatment plan.

13 alculated, along with other RBE models, on a treatment plan.

14 ce in conjunction with the discussion of the treatment plan.

15 s of a lesion, and determining the follow-up treatment plan.

16 should be carefully considered when making a treatment plan.

17 whether the results would modify the initial treatment plan.

18 ses and properly personalized prevention and treatment plans.

19 tient is crucial for developing personalized treatment plans.

20 unger, healthier populations when developing treatment plans.

21 undant systems and each may require specific treatment plans.

22 e level and add a developmental dimension to treatment plans.

23 perative to ensure successful individualized treatment plans.

24 erences in symptom evaluation and developing treatment plans.

25 ose a concern for large-scale antiretroviral treatment plans.

26 n and its effects may be a target for future treatment plans.

27 eement between claims-inferred care and NOPR treatment plans.

28 itis, and consequently significantly affects treatment plans.

29 s may facilitate development of personalized treatment plans.

30 ortion of visits that resulted in error-free treatment plans.

31 and immature teratoma (IT) to assist future treatment plans.

32 l and advanced disease leading to individual treatment plans.

33 about long-term prognosis, and personalizing treatment plans.

34 idual cancer patients to derive personalized treatment plans.

35 erthermia model to define focused ultrasound treatment plans.

36 and the potential for targeted and effective treatment plans.

37 urgent need for better diagnosis methods and treatment plans.

38 terest that may be relevant for radiotherapy treatment planning.

39 be used as a prognostic marker for tailored treatment planning.

40 a-analyses for inferences about etiology and treatment planning.

41 tially useful information that may influence treatment planning.

42 T which would result in better diagnosis and treatment planning.

43 f thyroid cancer patients and individualized treatment planning.

44 analysis tool for orthodontic diagnosis and treatment planning.

45 from secretin-enhanced MR imaging for their treatment planning.

46 corneal thickness were taken into account in treatment planning.

47 eta spectrum (PAS) disorder is essential for treatment planning.

48 renic nerve, all needed for PV cryoabalation treatment planning.

49 ies have an important place in diagnosis and treatment planning.

50 dicator of cancer stage and is important for treatment planning.

51 e assessed for use of PET during staging and treatment planning.

52 omab radioimmunotherapy for potential use in treatment planning.

53 ace, the evaluation of their advancement and treatment planning.

54 ion and prognostic evaluation and can change treatment planning.

55 y indicating careful assessment and specific treatment planning.

56 ility or the characterization of lesions for treatment planning.

57 ntary tool for assessing ischemic damage and treatment planning.

58 or the diagnosis of hip abnormalities and in treatment planning.

59 , only clinical parameters are important for treatment planning.

60 pies for alcohol dependence is important for treatment planning.

61 it is unrecognized at the time of radiation treatment planning.

62 e tumor process with sufficient accuracy for treatment planning.

63 de invaluable tools for accurate staging and treatment planning.

64 f a clinician when it comes to pre-operative treatment planning.

65 ecise risk stratification and individualized treatment planning.

66 ith 74 Gy of TRT utilizing three-dimensional treatment planning.

67 nd, if appropriate, enable interdisciplinary treatment planning.

68 rs are critical for subsequent prognosis and treatment planning.

69 ting this co-occurrence may be important for treatment planning.

70 stratification indices to establish optimal treatment planning.

71 d hemodynamics is essential in diagnosis and treatment planning.

72 prognosis for this cohort can lead to better treatment planning.

73 e to the range uncertainties incorporated in treatment planning.

74 iled dosimetry that may lead to improved MRT treatment planning.

75 t of novel molecular therapies, and targeted treatment planning.

76 g the efficacy of radiotherapy and radiation treatment planning.

77 nes on its necessity and use for periodontal treatment planning.

78 ed variable for clinical staging and aphasia treatment planning.

79 nsidered to have a potential major impact on treatment planning.

80 cations, diagnostic potential, and impact on treatment planning.

81 ce-informed approach to case formulation and treatment planning.

82 the tissue, which forms the basis of current treatment planning algorithms.

83 As part of standard treatment planning, all patients underwent SPECT imaging

84 After initial examination and treatment planning, all patients underwent the periodont

85 t model could be used as the backbone of the treatment planning, allowing optimization of the absorbe

86 activated sludge of a commercial wastewater treatment plan and identified as Gordonia species by 16S

87 ecific emergency medication and an emergency treatment plan and training in administration of emergen

88 facilitate the postoperative communication, treatment planning and analysis of surgical treatment of

89 nel had access to the latest developments in treatment planning and beam delivery and to all updated

90 on as well as information that is useful for treatment planning and cancer prevention.

91 er investigation to understand its impact on treatment planning and clinical trial design.

92 ubstantial technologic advances in radiation treatment planning and delivery have made possible exqui

93 tandardize imaging terminology to facilitate treatment planning and enable precise comparison of resu

94 3D cancer cell culture models to improve IRE-treatment planning and facilitate widespread clinical us

95 cellent technology for patient selection and treatment planning and follow-up.

96 margins have been reduced through the use of treatment planning and image-guidance technology.

97 rs deployed during focal therapies to inform treatment planning and in vivo monitoring in thin tissue

98 mation and selection of a treatment regimen; treatment planning and informed consent; ordering of tre

99 This technology may support novel treatment planning and monitoring approaches in oncology

100 oxia dynamics during radiotherapy to improve treatment planning and prognosis.

101 h as outcome assessment, neurocritical care, treatment planning and rapid, precision-diagnosis.

102 tomated, robust, and promising for live-time treatment planning and research applications.

103 ation may be more favorable for the areas of treatment planning and response evaluation.

104 imaging of tumors have become important for treatment planning and response monitoring.

105 cancer and use of C stage for multimodality treatment planning and risk stratification in prospectiv

106 Thus, detection of hypoxia can guide treatment planning and serve as a predictor of patient p

107 Challenges with IRE include complex treatment planning and the induction of intense muscle c

108 DG PET and MRI data may enable more reliable treatment planning and therapy monitoring of STS.

109 t of cancer, including screening, diagnosis, treatment planning and therapy monitoring.

110 on of extent of disease and may add value in treatment planning and treatment monitoring of high-grad

111 view current imaging modalities used in SBRT treatment planning and tumour assessment and review the

112 improving personalized drug development and treatment planning and ultimately, overall patient outco

113 inflammatory conditions in patients to guide treatment planning and undertake necessary interventions

114 dence of mortality was 11.65% under observed treatment plans and 10.10% under the intervention, yield

115 2C); and addressing goals of care, including treatment plans and end-of-life planning (as appropriate

116 The results of PET/CT can alter treatment plans and have particular use in guiding site-

117 ng those trauma patients early would improve treatment plans and resource allocation.

118 address medical update, patient preferences, treatment plan, and milestones for evaluating the treatm

119 and treatment outcome assessment, 2) implant treatment planning, and 3) anatomic characterization.

120 sonance imaging (MRI) for target definition, treatment planning, and closed-loop control of energy de

121 niques plays an important role in diagnosis, treatment planning, and follow-up.

122 is important for prognosis determination and treatment planning, and it has underscored an unmet need

123 shed method increasingly used for diagnosis, treatment planning, and monitoring in gliomas.

124 in clinical practice for diagnosis, staging, treatment planning, and response assessment, the transit

125 have become essential for cancer diagnosis, treatment planning, and surveillance.

126 inability of patients to follow through with treatment plans, and (c) emotional distress for patients

127 lopment of predictive models, individualized treatment plans, and novel therapeutic approaches, poten

128 l trials; lower adherence to medications and treatment plans; and psychosocial stressors relevant to

129 younger age, depression, and a complex drug treatment plan are associated with lower medication adhe

130 Thus, comprehensive treatment plans are necessary to optimize care.

131 its are vital in making a decision about the treatment plan as it can persist one year or more follow

132 necrosis in tumors is of prognostic value in treatment planning, as necrosis is associated with aggre

133 areas of radiation oncology for imaging and treatment planning, as well as for radiosensitization to

134 of teeth planned for extraction as part of a treatment plan at initial examination.

135 Offline MRI is already used for treatment planning at many institutions.

136 f-life decisions with clinicians to create a treatment plan based on patient wishes.

137 s may lead to optimization of individualized treatment planning based on pretreatment imaging.

138 also perform a dosimetric evaluation of the treatment plans based on pCT and rCT images and find the

139 ls suggest the possibility of individualized treatment plans based on recovery potential.

140 the ways in which clinicians develop patient treatment plans based on the results of those trials.

141 The treating oncologist indicated a treatment plan before and after biopsy to determine whet

142 essed physicians' diagnostic assessments and treatment plans before and after rapid response electroe

143 and substance use in patient assessments and treatment planning, both to prevent adverse transitions

144 atic LNs remains essential for prognosis and treatment planning, but a reliable noninvasive imaging t

145 accurately diagnosed so that an appropriate treatment plan can be developed.

146 patient participation in the decision of the treatment plan can be implemented.

147 he ocular surface, an accurate diagnosis and treatment plan can be made for patients presenting with

148 ients with NSCLC most likely to have irSAEs, treatment plans can be optimized before initiation of im

149 f complications make judgments about optimal treatment plans challenging.

150 linical features, and whether their previous treatment plan changed due to WES results.

151 to clinical and laboratory findings, cancer treatment plan (chemotherapy, radiotherapy, or surgery),

152 When formulating a treatment plan, clinicians should consider the patient's

153 have improved, but at the cost of increased treatment plan complexity and planning time.

154 her radiomics feature come from radiotherapy treatment planning CT can predict prognosis in locally a

155 attenuation correction CT, radiation therapy treatment planning CT, CAC screening CT, and low-dose CT

156 All patients' radiotherapy treatment planning CTs were collected.

157 ajor clinical role in guiding diagnostic and treatment planning decisions in patients with mental dis

158 e screened for enrollment, and 74 received a treatment-planning dose of HSA (131)I-MIBG.

159 cancer therapy, radiation dosimetry supports treatment planning, dose-response analyses, predictions

160 ngs could provide crucial information to aid treatment planning during stage III colon cancer.

161 edict radiation dose, as a means to increase treatment planning efficiency and improve radiotherapy p

162 ur could therefore play an important role in treatment planning, enabling treatment to be targeted in

163 lection of patients and for an adaptation of treatment planning, especially in selected patients (par

164 Because there is no cure for SRS, treatment plans focus on alleviating symptoms rather tha

165 eling, prenatal diagnostic procedures, and a treatment plan for delivery for both the mother and chil

166 k profile are fundamental in determining the treatment plan for each individual patient.

167 laying a definitive diagnosis or an adequate treatment plan for individual patients.

168 ans are an important component of a thorough treatment plan for minimizing risk to the IAN and optimi

169 atification for developing an individualized treatment plan for patients with thyroid cancer.

170 that reported the impact of PSMA PET on the treatment plan for prostate cancer patients with BCR.

171 on were completed in 7 weeks and changed the treatment plan for the patient.

172 st, a hindrance to selecting the appropriate treatment plan for, accurate genotype-phenotype correlat

173 Thirteen patients who had treatment planned for CTG on a single tooth were recruit

174 Twenty-four patients treatment planned for osseous surgery after completion o

175 ologic dosimetry (3D-RD) was used for (131)I treatment planning for an 11-y-old girl with differentia

176 However, when treatment planning for an immediate implant in the poste

177 systems have created confusion about optimal treatment planning for AYAs, a population that spans the

178 cond, the flow models can be used to improve treatment planning for cardiovascular disease.

179 ently applied prognostic criteria for use in treatment planning for childhood ALL.

180 omography (CBCT) for the diagnosis of and/or treatment planning for intrabony and furcation defects,

181 the use of CBCT for the diagnosis of and/or treatment planning for intrabony and furcation defects.

182 ing CBCT imaging for the diagnosis of and/or treatment planning for intrabony and/or furcation defect

183 Treatment planning for patients with MDS who are HCT can

184 Treatment planning for persistent pain in later life req

185 s that have examined the role of PSMA PET in treatment planning for prostate cancer patients with bio

186 h can potentially enhance long-term care and treatment planning for psychiatric patients.

187 nstrate the importance of considering TCP in treatment planning for radioembolization.

188 etecting brain metastasis with MRI to aid in treatment planning for SRS.

189 possibility of real-time re-optimization of treatment plans for Adaptive Radiotherapy (ART).

190 s of word reading and can be used to develop treatment plans for individuals with reading disabilitie

191 fic factors, could be useful when developing treatment plans for nonmalignant diseases.

192 These results warrant individualized treatment plans for patients with heterogeneous genetic

193 highlights key diagnostic tools and optimal treatment plans for SCFE.

194 ificantly more likely to develop appropriate treatment plans for standardized patients with contextua

195 [95% CI, 76%-86%]) or developing appropriate treatment plans for standardized patients with medical i

196 ng guideline-based therapies when developing treatment plans for teens with asthma.

197 Accordingly, to assist in designing treatment plans for therapeutic radiopharmaceuticals, an

198 A treatment plan from the specialist should have clear dir

199 y aid diagnosis and provide patient-specific treatment plans from a 3D scan alone, to help efficient

200 elae for accurate assessment of severity and treatment planning, if indicated.

201 Optimal multidisciplinary treatment planning improves the outcome of each patient

202 Overall, PET/CT resulted in starting a new treatment plan in 70.8% of patients with positive residu

203 dren with glaucoma should be included in the treatment plan in addition to medical and surgical treat

204 sing a desire for hastened death; document a treatment plan in diagnosed patients; and follow up resp

205 amily and child about the need for an asthma treatment plan in school and support the school nurse me

206 iew of the impact of imaging in urolithiasis treatment planning in 2013.

207 the crucial role of endoscopic ultrasound in treatment planning in patients with gastric mucosa-assoc

208 For optimal treatment planning in radionuclide therapy, robust tumor

209 w become routine in preoperative staging and treatment planning in the community and appears to be be

210 iable adjunctive tool for both diagnosis and treatment planning in the field of dentistry.

211 Important modifications to the original treatment plan included avoidance of systemic therapy (1

212 The complete treatment plan included neoadjuvant CRT (cisplatin + 5-f

213 Post-NaF PET treatment plans, including combinations of 2 modes of th

214 e patient's specific situation (for example, treatment plan, insurance coverage) and of the resources

215 ient participation in the elaboration of the treatment plan is expected to substantially improve the

216 e disease score provides evidence that a new treatment plan is needed.

217 A multidimensional treatment plan is then formulated targeting the pain mec

218 imetry becomes obvious when the objective of treatment planning is to achieve disease cures, safely,

219 Formulation of policy and individual treatment plans is hampered by lack of data regarding th

220 rent standard practice for radioembolization treatment planning makes use of nuclear medicine imaging

221 ourse of SUD treatment outcomes and that SUD treatment planning may benefit from identifying and addr

222 east emphasis on chemotherapy in the overall treatment plan (mean [SEM] score, 2.60 [0.07]; P = .001)

223 60 total patients, 46 underwent the complete treatment plan (median age: 60.1 years; adenocarcinoma:

224 MRI findings resulted in treatment plan modification for 39 of 79 (49.4%) men ove

225 e provide the basis for a paradigm change in treatment planning, monitoring, and adaptation.

226 therapies exist for hyperhidrosis, and each treatment plan must be evaluated on a patient-by-patient

227 could be advantageous in therapy selection, treatment planning, objective response monitoring and fo

228 with BCR, with modifications to the original treatment plan occurring among half the patients.

229 This could be useful in the treatment plan of immediate loading cases.

230 nd established in the detection, staging and treatment planning of cervical cancer and for identifyin

231 coverage and the critical structures in the treatment planning of helical tomotherapy (TOMO), volume

232 luable tool in the diagnosis, follow-up, and treatment planning of neuroendocrine tumor (NET).

233 valuable role in the diagnosis, staging, and treatment planning of the disease.

234 In current treatment plans of intensity-modulated proton therapy, h

235 ulation of the study question, including the treatment plans of interest, can provide navigation arou

236 essure before its onset and optimize medical treatment plans of pre-hypertension and hypertension.

237 The surgical treatment plans on the basis of PET/CT findings may be c

238 ce spacing) were acquired and (12)C ion beam treatment planning (optimal accelerator energies, beam p

239 logic considerations are made at the time of treatment planning or delivery.

240 icians (e.g., failure to specify end-of-life treatment plans or to secure an ICU bed prior to electiv

241 hemoglobin A1c target ranges, individualized treatment plans, outpatient pharmacologic treatment, glu

242 Before establishment of treatment plans, patients were administered a survey inc

243 ght be used in high-risk PC before radiation treatment planning, potentially affecting this planning

244 formation from (18)F-fluciclovine PET in the treatment-planning process led to significant difference

245 formation from (18)F-fluciclovine PET in the treatment-planning process led to significant difference

246 n of aesthetic evaluation, smile design, and treatment-planning processes.

247 ilable treatment options integrated into the treatment plan properly.

248 he intervention with outcomes under observed treatment plans provides meaningful information about th

249 normal brain, while maintaining the similar treatment plan qualities on the thirteen patients treate

250 Controversy exists in treatment planning relative to the attempt of saving a t

251 se and treated them with a reduced-intensity treatment plan (RELLA05).

252 evaluation, followed by a psychoeducational/treatment planning session.

253 As part of her multidisciplinary treatment plan, she consulted with two plastic surgeons

254 An individualised treatment plan should be devised depending on the clinic

255 Response prediction and treatment planning should account for tumour response he

256 Treatment planning should incorporate contributing facto

257 ith MLBO and if resection is not part of the treatment plan, stenting is safe and improves the effici

258 hese results begin to explain differences in treatment planning strategies between glass and resin ra

259 shed light on optimal methods of diagnosis, treatment planning, surgery, and quantification of outco

260 am arrangements and can be integrated in the treatment planning system for clinical application direc

261 In each case, the respective treatment-planning target volume expansion (PTV, PTV1, o

262 lovine in modifying the defined clinical and treatment-planning target volumes in postprostatectomy p

263 For each patient, the clinical and treatment-planning target volumes that would have been t

264 st as a core member of the multidisciplinary treatment planning team, it is crucial for imagers to re

265 Treatment plans tend to focus on the disease rather than

266 pathogenic mechanisms, our report includes a treatment plan that prevents unnecessary discontinuation

267 tients, and use their expertise to formulate treatment plans that reflect patient preferences and are

268 inicians should explain and advocate for the treatment plan they believe is appropriate.

269 justing or adding supportive measures to the treatment plan to maximize successful outcomes.

270 develop and implement a modeling method for treatment planning to determine the optimal combination

271 llary anterior teeth and necessitate careful treatment planning to prevent future complications.

272 ntial to enable comprehensive evidence-based treatment plans to be implemented quickly, rather than i

273 d dermatologists, who provided diagnoses and treatment plans to primary care physicians (PCPs).

274 y risk under observed antiretroviral therapy treatment plans to the 5-year mortality risk that would

275 should be discussed and initiated with early treatment planning, to allow the best chance for future

276 gical applications for better individualized treatment planning towards precision medicine.

277 Treatment planning under International Society of Paedia

278 The secondary endpoints were changes in treatment plan, use of resources, and changes in disposi

279 tide and the activity should be optimized in treatment planning using the proposed method.

280 f extrahepatic deposition, and sometimes for treatment planning, using a partition model.

281 The initial treatment plan was based on the results from conventiona

282 In 40.9% of patients, the treatment plan was changed after the scans, owing mainly

283 The PET/CT-informed surgical treatment plan was changed in 51 of 237 participants (22

284 Pre-PET/CT treatment plan was compared with treatment provided.

285 thorough oral and periodontal examination, a treatment plan was developed that included oral hygiene

286 In prostate FOM, the concordance across all treatment plans was lower if the patients had ADT claims

287 cians' confidence in their own diagnosis and treatment plan were also improved.

288 Clinical stage, risk assessment, and treatment plan were determined with and without the cont

289 Three radiation treatment plans were designed for each patient.

290 Ten Gray treatment plans were repeatedly administered, using penc

291 Treatment plans were reviewed for quality assurance (QA)

292 Added value was determined by changes in treatment plan when (68)Ga-DOTATATE PET/CT results were

293 tion or elimination of opioid use as part of treatment plan when contemplating 10 kHz SCS.

294 ified during stereotactic radiosurgery (SRS) treatment planning, which is time consuming and potentia

295 atomical imaging provides reference data for treatment planning, while real-time temperature monitori

296 ing clinicians establish a more customizable treatment plan with the cut-off point identifying patien

297 specific treatment arc, and (e) generates a treatment plan with the optimized angles.

298 We compared organ-specific dosimetry for treatment planning with the whole-body dose-assessment m

299 uestionnaire before the scan to indicate the treatment plan without (68)Ga-PSMA-11 PET/CT information

300 onnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediate